

Imsidolimab Biosimilar - Research Grade

Product Code: ICH5245

More Information

Species Reactivity: Human

Target: IL1RL2

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Imsidolimab Biosimilar - Research Grade

Antibodies against the same target: [Spesolimab Biosimilar - Research Grade \(ICH5882\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q9HB29

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of imsidolimab, an anti-IL-36 receptor (IL-36R / IL1RL2) monoclonal antibody, produced for research use only. It reproduces the target specificity of the originator biologic (a humanized IgG4 antibody that binds IL-36R and antagonizes IL-36 signaling) in a research-grade format, and it is not the clinical drug and is not intended for human or veterinary use. The recombinant format makes it useful as a reference reagent and positive control in binding, blocking, and neutralization assays against human IL-36R, for benchmarking in-house or biosimilar candidate antibodies, and for supporting antibody-engineering and preclinical characterization work. It is supplied unconjugated so researchers can pair it with their own detection systems. Low-endotoxin grades (research grade under 1 EU/mg; ultra-low under 0.5 EU/mg) and bulk milligram-to-gram quantities are available to support cell-

based assays, screening cascades, and scale-up. Because IL-36R is a human target, the reagent is oriented toward functional and in-vitro applications rather than routine rodent in-vivo dosing. IL1RL2 (Q9HB29), also called IL-36R, IL-1Rrp2, or IL1RRP2, is a member of the interleukin-1 receptor family. It is the ligand-binding receptor for the IL-36 cytokines IL-36 alpha, IL-36 beta, and IL-36 gamma. On ligand engagement, IL-36R recruits the shared accessory protein IL1RAP (IL-1RAcP) to form a heterodimeric signaling complex that drives MyD88-dependent activation of NF-kappaB and MAPK pathways, producing proinflammatory responses. Signaling is normally restrained by the endogenous antagonist IL-36Ra, which binds IL-36R without recruiting the coreceptor. IL-36R is expressed prominently in epithelial and barrier tissues, particularly skin, where the IL-36 axis amplifies the IL-23/IL-17/IL-22 pathway. Dysregulated IL-36R signaling is central to pustular skin inflammation, including generalized pustular psoriasis and palmoplantar pustulosis, making the receptor a key node in epithelial autoinflammation.

Other names: IL-36 receptor, IL-36R, Interleukin-1 receptor-related protein 2, IL-1Rrp2, Interleukin-1 receptor-like 2

Specificity: Detects human IL1RL2

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks